Objective: To evaluate the treatment outcomes of patients with hydatidiform mole at Kien Giang Obstetrics and Pediatrics Hospital during the period 2022–2024.
Subject and method: A retrospective descriptive study was conducted on 55 patients diagnosed with hydatidiform mole confirmed by histopathology and treated at the Department of Obstetrics, Kien Giang Obstetrics and Pediatrics Hospital, from January 2022 to December 2024. Data were collected from medical records, including clinical and paraclinical characteristics, treatment methods, and follow-up outcomes. Data analysis was performed using SPSS software version 20.0.
Results: High-risk molar pregnancies accounted for 60%, mainly complete moles (45.5%). The primary treatment method was uterine evacuation combined with prophylactic chemotherapy using Methotrexate plus Folinic Acid (65.5%). Most patients required two evacuations (70.9%), and 58.2% experienced vaginal bleeding lasting less than 5 days. Post-evacuation ultrasound revealed retained molar tissue in 80% of cases, predominantly in complete moles (72.7%). The mean serum β-hCG level after evacuation was significantly higher in complete moles than in partial moles (76,422 vs. 1,563 mIU/mL; p = 0.007).
Conclusion: Complete hydatidiform mole remains the predominant type with a higher risk of malignant transformation. Uterine evacuation combined with prophylactic Methotrexate plus Folinic Acid therapy effectively reduces complications and improves treatment outcomes. Regular monitoring of β-hCG levels and follow-up ultrasound plays a crucial role in early detection of persistent gestational trophoblastic disease.